Entry Point Capital, LLC Summit Therapeutics Inc. Put Options Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Put Options
0 transactions
Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
---|
Others Institutions Holding SMMT
# of Institutions
138Shares Held
64.4MCall Options Held
1.06MPut Options Held
1.02M-
Baker Bros. Advisors LP New York, NY23.2MShares$290 Million2.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.82MShares$110 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$98.7 Million0.0% of portfolio
-
State Street Corp Boston, MA4.12MShares$51.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.96MShares$37 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $2.52B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...